Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women

American Heart Journal

Volumn 147, Issue 6, 2004, Pages 1093-1099

  Stamatelopoulos, Kimon S ^a,b   Lekakis, John P ^a   Poulakaki, Nikiforita A ^a   Papamichael, Christos M ^a   Venetsanou, Kyriaki ^a   Aznaouridis, Konstantinos ^a   Protogerou, Athanasios D ^a   Papaioannou, Theodoros G ^a   Kumar, Sanjay ^a   Stamatelopoulos, Stamatios F ^a  

^a ALEXANDRA HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN;

ADULT; AGED; ANALYTICAL ERROR; ARTERY DILATATION; ARTERY INTIMA PROLIFERATION; ARTICLE; BRACHIAL ARTERY; BREAST CANCER; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INDICATION; FEMALE; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; PULSE WAVE;

AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CARCINOMA IN SITU; CAROTID ARTERIES; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PULSATILE FLOW; TAMOXIFEN; TUNICA INTIMA; TUNICA MEDIA;

EID: 3042815057     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.12.029     Document Type: Article

References (44)

1. Mendelsohn M., Karras R. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 340:1999;1801-1811
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women principle results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333
3. Grady D., Hemington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 288:2002;49-57
4. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med. 339:1998;1609-1618
5. McDonald C.C., Steward H.J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ. 303:1991;435-437
6. Rutqvist L.E., Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen the Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 85:1993;1398-1406
7. Fisher B., Constantino J., Wickerham L., et al. Tamoxifen for prevention of breast cancer report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1998;1371-1388
8. Riggs B.L., Hartmann L.C. Selective estrogen-receptor modulators-mechanisms of action and application to practice. N Engl J Med. 348:2003;618-629
9. Anker G., Lonning P.E., Ueland P.M., et al. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer. 60:1995;365-368
10. Love R.R., Wiebe D.A., Feyzi J.M., et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 86:1994;1534-1539
11. Cushman M., Constantino J.P., Tracy R.P., et al. Tamoxifen and cardiac risk factors in healthy women suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol. 21:2001;255-261
12. Herrington D.M., Potvin Klein K. Effects of SERMs on important indicators of cardiovascular health lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues. 11:2001;95-102
13. Herrington D.M., Brosnihan K.B., Pusser B.E., et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab. 86:2001;4216-4222
14. Williams J.K., Wagner J.D., Li Z., et al. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol. 17:1997;403-408
15. Reckless J., Metcalfe J.C., Grainger D.J. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation. 95:1997;1542-1548
16. Grainger D.J., Kemp P.R., Metcalfe J.C., et al. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med. 1:1995;74-79
17. Tashiro H., Shimokawa H., Yamamoto K., et al. Altered plasma levels of cytokines in patients with ischemic heart disease. Coron Art Dis. 8:1997;143-147
18. Fathi R., Marwick T.H. Noninvasive tests of vascular function and structure why and how to perform them. Am Heart J. 141:2001;694-703
19. Herrington D.M., Werbel B.L., Riley W.A., et al. Individual and combined effects of estrogen/progestin and lovastatin on lipids and flow-mediated vasodilatation in postmenopausal women with coronary artery disease. J Am Coll Cardiol. 33:1999;2030-2037
20. Westendorp I.C.D., Veld B.A., Bots M.I., et al. Hormone replacement therapy and intima-media thickness of the common carotid artery the Rotterdam study. Stroke. 30:1999;2562-2567
21. Simon T., Boutouyrie P., Simon J.M., et al. Influence of tamoxifen on carotid intima-media thickness in postmenopausal women. Circulation. 106:2002;2925-2929
22. Clarke S.C., Schofield P.M., Grace A.A., et al. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation. 103:2001;1497-1502
23. Ong P.J.L., Linardou H., Graham H.A., et al. Tamoxifen is not detrimental to endothelial function in postmenopausal women with breast cancer. Am Heart J. 142:2001;e6
24. Figtree G.A., Webb C.M., Collins P. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. J Pharmacol Exp Ther. 295:2000;519-523
25. Saitta A, Altavilla D, Cucinotta D, et al. Randomized double-blind placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 200;21:1512-9
26. Ceresini G., Marchini L., Rebecchi I., et al. Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women. Atherosclerosis. 167:2003;121-127
27. Herrington D.M., Pusser B.E., Riley W.A., et al. Cardiovascular effects of droloxifene a new Selective estrogen receptor modulator, in healthy postmenopausal women. Arterioscler Thromb Vasc Biol. 20:2002;1606-1612
28. Mailloux D., Grenet K., Bruneel D., et al. Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol. 80:2001;442-449
29. Salgado R., Junius S., Benoy I., et al. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 103:2003;642-646
30. Bruunsgaard H. Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. Eur Cytokine Netw. 13:2002;389-391
31. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 340:1992;1111-1115
32. Joannides R., Haefeli W.E., Linder L., et al. Nitric oxide is responsible for flow-mediated dilatation of human peripheral conduit arteries in vivo. Circulation. 91:1995;1314-1319
33. Simon A., Gariepy J., Chinori G., et al. Intima-media thickness a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 20:2002;159-169
34. De Groot E., Joukema W.J., Montauban van Swijndregi A.D., et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol. 31:1998;1561-1567
35. O'Rourke M.F., Pauca A., Jiang X.J. Pulse wave analysis. Br J Clin Pharmacol. 51:2001;507-522
36. Papaioannou T.G., Lekakis J.P., Dagre A.G., et al. Arterial compliance is an independent factor predicting acute hemodynamic performance of intra-aortic balloon counterpulsation. Int J Artif Organs. 24:2001;478-483
37. Reddy K.G., Nair R.N., Sheehan H.M., et al. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol. 23:1994;833-843
38. Guetta V., Lush R.M., Figg W.D., et al. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol. 76:1995;1072-1073
39. Leung W.H., Lau C.P., Wong C.K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 341:1993;1496-1500
40. Candipan R.C., Wang B.Y., Buitrago R., et al. Regression or progression dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol. 16:1996;44-50
41. Grainger D.J., Metcalfe J.C. A pivotal role for TGF-beta in atherogenesis? Biol Rev Camb Philos Soc. 70:1995;571-596
42. Kinlay S., Creager M.A., Fukumoto M., et al. Endothelium-derived nitric oxide regulates arterial elasticity in human arteries in vivo. Hypertension. 38:2001;1049-1053
43. Berrett-Connor E., Grady D., Sashegyi A., et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women four-years results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 287:2002;847-857
44. Mosca L., Berrett-Connor B., Wegner N.K., et al. Design and methods of the Raloxifene Use for the Heart (RUTH) study. Am J Cardiol. 88:2001;392-395